Published in Can J Physiol Pharmacol on September 01, 1985
Protective effects of bradykinin on the ischaemic heart: implication of the B1 receptor. Br J Pharmacol (1993) 0.96
Chronophysiological view on changes of the electrical stability of the heart and heart rate under pentobarbital sodium and ketamine/xylazine anesthesia in a hypoventilation-reoxygenation rat model. Exp Clin Cardiol (2004) 0.75
N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction. Circulation (1994) 2.05
Sildenafil (Viagra) prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. Circulation (2000) 1.91
Selective binding of (3H)gibberellin A1 by protein fractions from dwarf pea epicotyls. Proc Natl Acad Sci U S A (1974) 1.84
Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial. Kidney Int (2007) 1.67
Effect of Abscisic Acid on Uptake and Metabolism of [H]Gibberellin A(1) and [H]Pseudogibberellin A(1) by Barley Half-seeds. Plant Physiol (1973) 1.61
Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study. Eur Heart J (1998) 1.52
Cycle length dynamics at the onset of postinfarction ventricular tachycardias induced in canines: dependence on interval-dependent excitation properties of the reentrant substrate. J Cardiovasc Electrophysiol (2000) 1.48
The serum porphobilinogen and hepatic porphobilinogen deaminase in normal and porphyric individuals. J Lab Clin Med (1971) 1.47
Regulation of norepinephrine release from cardiac sympathetic fibers in the dog by presynaptic alpha- and beta-receptors. Circ Res (1977) 1.37
Circulating catecholamine levels in human and experimental hypertension. Circ Res (1976) 1.37
Domperidone should not be considered a no-risk alternative to cisapride in the treatment of gastrointestinal motility disorders. Circulation (2000) 1.33
Repression of the overproduction of porphyrin precursors in acute intermittent porphyria by intravenous infusions of hematin. Proc Natl Acad Sci U S A (1971) 1.33
N-acetyl-cysteine decreases the matrix-degrading capacity of macrophage-derived foam cells: new target for antioxidant therapy? Circulation (1998) 1.33
Epicardial and endocardial mapping of ventricular tachycardia in patients with myocardial infarction. Is the origin of the tachycardia always subendocardially localized? Circulation (1991) 1.25
Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol (1994) 1.24
Dysfunction of the beta- and alpha-adrenergic systems in a model of congestive heart failure. The pacing-overdrive dog. Circ Res (1991) 1.22
Influence of respiration on heart rate and blood pressure fluctuations. J Appl Physiol (1985) (1993) 1.19
Effect of hematin in acute porphyric relapse. Ann Intern Med (1973) 1.19
Transitory renal failure following rapid administration of a relatively large amount of hematin in a patient with acute intermittent porphyria in clinical remission. Acta Med Scand (1978) 1.17
Catecholamine metabolism in experimental hypertension in the rat. Circ Res (1967) 1.17
Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clin Cancer Res (1998) 1.17
Effects of hematin in hepatic porphyria. Further studies. Ann Intern Med (1975) 1.14
Supersensitivity of the isolated rat heart after chemical sympathectomy with 6-hydroxydopamine. Can J Physiol Pharmacol (1971) 1.10
Correlation between the response of the heart to sympathetic stimulation and the release of endogenous catecholamines into the coronary sinus of the dog. Circ Res (1975) 1.09
Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma. Clin Cancer Res (1998) 1.09
Use of hematin in the acute attack of the "inducible" hepatic prophyrias. Adv Intern Med (1978) 1.07
The mechanism of irreversible adrenergic blockade by N-carbethoxydihydroquinolines--model studies with typical serine hydrolases. Biochem Pharmacol (1969) 1.05
Enhanced superoxide anion formation in vascular tissues from spontaneously hypertensive and desoxycorticosterone acetate-salt hypertensive rats. J Hypertens (2001) 1.05
Catecholamines in coronary sinus during exercise in man before and after training. J Appl Physiol Respir Environ Exerc Physiol (1977) 1.04
Cardiac responses to electrical stimulation of discrete loci in canine atrial and ventricular ganglionated plexi. Am J Physiol (1990) 1.04
A reduction in the accumulation of H3-norepinephrine in experimental hypertension. Life Sci (1966) 1.03
Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects. Clin Pharmacol Ther (1996) 1.01
Direct evidence of caeruloplasmin antioxidant properties. Mol Cell Biochem (1998) 0.99
Synthetic C5a receptor agonists. Pharmacology, metabolism and in vivo cardiovascular and hematologic effects. Biochem Pharmacol (1993) 0.98
Different effects of nifedipine and amlodipine on circulating catecholamine levels in essential hypertensive patients. J Hypertens (1998) 0.98
Extracellular matrix modulates macrophage functions characteristic to atheroma: collagen type I enhances acquisition of resident macrophage traits by human peripheral blood monocytes in vitro. Arterioscler Thromb Vasc Biol (1998) 0.97
Impaired basal sympathetic tone and alpha1-adrenergic responsiveness in association with the hypotensive effect of melatonin in spontaneously hypertensive rats. Am J Hypertens (1998) 0.97
Properties of acebutolol in twenty patients with cardiac arrhythmias. Eur J Clin Pharmacol (1975) 0.96
Protective effects of bradykinin on the ischaemic heart: implication of the B1 receptor. Br J Pharmacol (1993) 0.96
Increased plasma catecholamine levels in patients with symptomatic mitral valve prolapse. Am J Med (1982) 0.96
Stability of delta-aminolevulinic acid and porphobilinogen in urine under varying conditions. Clin Chem (1968) 0.95
Effect of enalaprilat on bradykinin and des-Arg9-bradykinin release following reperfusion of the ischaemic rat heart. Br J Pharmacol (1995) 0.95
The heart reinnervates after transplantation. Ann Thorac Surg (2000) 0.95
Activation of neurohumoral systems in postinfarction left ventricular dysfunction. J Am Coll Cardiol (1993) 0.95
Postulated deficiency of hepatic heme and repair by hematin infusions in the "inducible" hepatic porphyrias. Proc Natl Acad Sci U S A (1977) 0.93
Negative inotropic and chronotropic effects of oxytocin. Hypertension (2001) 0.93
Mediation by B1 and B2 receptors of vasodepressor responses to intravenously administered kinins in anaesthetized dogs. Br J Pharmacol (1993) 0.93
Inhibition by cyclic AMP of basal and induced inositol phosphate production in cultured aortic smooth muscle cells from Wistar-Kyoto and spontaneously hypertensive rats. J Hypertens (1996) 0.92
Plasma norepinephrine response to exercise before and after training in humans. J Appl Physiol Respir Environ Exerc Physiol (1981) 0.92
Abnormal storage of norepinephrine in experimental hypertension in the rat. Circ Res (1967) 0.91
Acute and chronic cardiovascular effects of 6-hydroxydopamine in dogs. Circ Res (1972) 0.91
Cardiovascular effects of Buthus martensii (Karsch) scorpion venom. Toxicon (1994) 0.91
Ligand-dependent regulation of plasmid-based transgene expression in vivo. Hum Gene Ther (1999) 0.91
Effects of antihypertensive therapies on the sympathetic nervous system. Can J Cardiol (1999) 0.90
Regional distribution of atrial electrical changes induced by stimulation of extracardiac and intracardiac neural elements. J Thorac Cardiovasc Surg (1995) 0.90
Degeneration and regrowth of adrenergic nerve fibers in the rat peripheral tissues after 6-hydroxydopamine. Can J Physiol Pharmacol (1971) 0.90
The clinical evaluation of hypertension. Can Fam Physician (1985) 0.89
Effects of Buthus martensii Karsch scorpion venom on the release of noradrenaline from in vitro and in vivo rat preparations. Can J Physiol Pharmacol (1994) 0.89
Down-regulation of the pharmacokinetic-pharmacodynamic response to interleukin-12 during long-term administration to patients with renal cell carcinoma and evaluation of the mechanism of this "adaptive response" in mice. Clin Pharmacol Ther (1999) 0.89
Repression by hematin of porphyrin biosynthesis in erythrocyte precursors in congenital erythropoietic porphyria. Proc Natl Acad Sci U S A (1974) 0.89
Markedly different effects on ventricular remodeling result in a decrease in inducibility of ventricular arrhythmias. J Am Coll Cardiol (1994) 0.89
Effects of 6-hydroxydopamine on the canine sinus node. Circ Res (1971) 0.88
Plasma catecholamines in acute myocardial infarction. Am Heart J (1979) 0.88
Development and in vivo evaluation of metabolically resistant antagonists of B1 receptors for kinins. J Pharmacol Exp Ther (1993) 0.88
Overexpression of Gi-proteins precedes the development of DOCA-salt-induced hypertension: relationship with adenylyl cyclase. Cardiovasc Res (1998) 0.88
Hematin therapy in porphyric attacks. Klin Wochenschr (1980) 0.87
The effects of lidocaine on intracellular and extracellular potentials, activation, and ventricular arrhythmias during acute regional ischemia in the isolated porcine heart. Circ Res (1981) 0.86
Effects of chronic N-acetylcysteine treatment on the actions of peroxynitrite on aortic vascular reactivity in hypertensive rats. J Hypertens (2001) 0.86
Termination of sustained ventricular tachycardia by ultrarapid subthreshold stimulation in humans. Circulation (1988) 0.86
Demonstration of the production of oxygen-centered free radicals during electrolysis using E.S.R. spin-trapping techniques: effects on cardiac function in the isolated rat heart. Free Radic Biol Med (1998) 0.86
The sympathetic system in hypertension. Clin Endocrinol Metab (1977) 0.85
The kinin B1 receptor antagonist SSR240612 reverses tactile and cold allodynia in an experimental rat model of insulin resistance. Br J Pharmacol (2007) 0.85
Abnormal regulation of cytosolic free calcium in vascular endothelial cells from spontaneously hypertensive rats. J Hypertens (1995) 0.85
Increased plasma catecholamines in patients with Friedreich's ataxia. Can J Neurol Sci (1982) 0.85
Time-frequency dynamics in neurally mediated syncope. Clin Auton Res (1992) 0.85
Abnormal cardiovascular reactivity in borderline and mild essential hypertension. Hypertension (1991) 0.85
Transient ischemia inhibits nonexocytotic release of norepinephrine following sustained ischemia in rat heart: is bradykinin involved? Can J Physiol Pharmacol (1997) 0.84
Evaluation of arrhythmic causes of syncope: correlation between Holter monitoring, electrophysiologic testing, and body surface potential mapping. Am Heart J (1991) 0.84
Sympathoadrenal mechanisms underlying cardiovascular responses to intrathecal substance P in conscious rats. J Cardiovasc Pharmacol (1990) 0.84
Increased apparent norepinephrine release rate in anesthetized DOCA-salt hypertensive rats. Clin Exp Hypertens A (1985) 0.84
Effect of intravenous and oral calcium antagonists (diltiazem and verapamil) on sustenance of atrial fibrillation. Am J Cardiol (1988) 0.84
Antiarrhythmic effects of ceruloplasmin during reperfusion in the ischemic isolated rat heart. Can J Physiol Pharmacol (1995) 0.84
Functional desensitization to isoproterenol without reducing cAMP production in canine failing cardiocytes. Am J Physiol Regul Integr Comp Physiol (2001) 0.84
Effects of atenolol and hydrochlorothiazide on blood pressure and plasma catecholamines in essential hypertension. Hypertension (1983) 0.84
Dynamics of heart rate response to sympathetic nerve stimulation. Am J Physiol (1998) 0.84
Hematin treatment of acute porphyria. Early remission of an almost fatal relapse. JAMA (1976) 0.84
Evidences supporting an increased sympathetic tone and reactivity in a subgroup of patients with essential hypertension. Clin Exp Hypertens (1980) 0.84
Clinical applications of BSM. J Electrocardiol (1995) 0.84
Mapping of ventricular tachycardia induced by programmed stimulation in canine preparations of myocardial infarction. Circulation (1984) 0.83
In vivo B2-receptor-mediated negative chronotropic effect of bradykinin in canine sinus node. Am J Physiol (1993) 0.83
Protection of myocardial tissue against deleterious effects of oxygen free radicals by ceruloplasmin. Arzneimittelforschung (1995) 0.83
Protective effects of ceruloplasmin against electrolysis-induced oxygen free radicals in rat heart. Can J Physiol Pharmacol (1991) 0.83